D07.3

Clinical Causes: Persistent infection with high-risk strains of human papillomavirus (HPV), especially types 16 and 18 Genetic predispositions that affect cell growth and repair mechanisms Weakened immune system due to conditions like HIV/AIDS or immunosuppressive therapy Repeated exposure to carcinogens such as tobacco smoke or certain chemicals Personal or family history of genital or related cancers

Key Symptoms: Often asymptomatic; many cases are discovered during routine examinations Abnormal vaginal bleeding, especially after intercourse or between menstrual periods Unusual vaginal discharge that may be watery, bloody, or foul-smelling Presence of visible or felt lesions or plaques on examination of the vulva, cervix, or other genital organs Discomfort or pain during sexual intercourse

Diagnosis Path: Diagnosis of CIS often involves a combination of procedures to identify abnormal cell changes in the female genital organs. These include: - **Pelvic examination:** Visual inspection of the vulva, vagina, and cervix to detect any visible lesions or abnormalities. - **Pap smear (Pap test):** Collection of cells from the cervix to identify atypical or precancerous changes. - **Colposcopy:** A detailed examination of the cervix and vaginal tissues using a special microscope to look for abnormal areas. - **Biopsy:** Sampling of tissue from suspicious areas for microscopic examination, which confirms the presence of carcinoma in situ. - **HPV testing:** Identifying high-risk HPV strains associated with cervical and other genital cancers.

Treatment Protocols: Management of carcinoma in situ of female genital organs involves the removal or destruction of abnormal cells to prevent progression to invasive cancer. Treatment options include: - **Surgical excision:** Removal of affected tissue, which may involve local excision, laser therapy, or more extensive procedures depending on the location and extent. - **Cryotherapy:** Freezing abnormal cells to destroy them. - **Vaporization:** Using laser or thermal energy to eliminate precancerous areas. - **Topical medications:** Application of immune response modifiers or other topical agents in some cases. - **Regular follow-up:** Continuous monitoring with Pap smears and clinical examinations to detect any recurrence or new lesions. The choice of treatment depends on the size, location, and extent of the CIS, as well as the patient's overall health and preferences.